In vitro and in vivo transfection of p21 gene enhances cyclosporin A-mediated inhibition of lymphocyte proliferation.
Cyclosporine has potent antiproliferative properties, some of which may be via the induction of the cyclin inhibitor p21. In this study, we describe the effects of in vitro and in vivo transfection of p21 in lymphoid and nonlymphoid cells. For in vitro studies, p21 sense plasmid DNA was transfected in A-549 cells (lung adenocarcinoma cell line) and Jurkat cells (human lymphoid cell line). This in vitro transfection of p21 resulted in the inhibition of spontaneous and mitogen-induced cellular proliferation ([3H]thymidine uptake) and also augmented the antiproliferative effects of cyclosporine. In vivo transfection of p21 was accomplished in mice via the i.m. injection of p21 sense plasmid DNA complexed with cationic lipids. As was the case in the cell lines, p21 mRNA was augmented in heart, lung, liver, and spleen 7 days after i.m. injection of p21 sense plasmid DNA. The mitogen (anti-CD3)-induced proliferation of splenocytes from p21-overexpressing mice was significantly decreased, and again this effect was augmented by cotreatment with cyclosporine. These novel findings demonstrate the potential of targeting the cell cycle directly to inhibit alloimmune activation in organ transplantation. This may serve as an alternate strategy to induce immunosuppression, perhaps with less toxicity than that which is seen with conventional immunosuppressive agents.
The Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA. akkhanna@mcw.edu
A K
AK
Khanna
J D
JD
Hosenpud
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000235:genetics*; D000818:Animals; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins / Q000008:administration & dosage* / Q000096:biosynthesis / Q000235:genetics* / Q000502:physiology; D016572:Cyclosporine / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000276:immunology; D006131:Growth Inhibitors / Q000494:pharmacology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007273:Injections, Intramuscular; D019169:Jurkat Cells; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008213:Lymphocyte Activation / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D051379:Mice; D009206:Myocardium / Q000378:metabolism; D009928:Organ Specificity / Q000235:genetics / Q000276:immunology; D010957:Plasmids / Q000008:administration & dosage / Q000138:chemical synthesis / Q000276:immunology; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D014162:Transfection / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; C493956:CDKN1A protein, human; C493957:Cdkn1a protein, mouse; D050759:Cyclin-Dependent Kinase Inhibitor p21; D016213:Cyclins; D006131:Growth Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine